CEO & Executive Director, Inova Schar Cancer Institute
Donald “Skip” Trump, MD, joined the Inova Schar Cancer Institute (ISCI) as its Chief Executive Officer on January 5, 2015. He most recently served as president and CEO of Roswell Park Cancer Institute (RPCI) in Buffalo, NY. Roswell Park Cancer Institute is one of the nation’s nationally designated cancer centers. Under Trump’s 13-year leadership, Roswell Park substantially expanded its patient care, research and education programs.
Dr. Trump is a medical oncologist who specializes in the treatment of patients with genitourinary cancers, especially prostate and bladder cancer. He has received peer reviewed research funding from the National Cancer Institute, the Department of Defense and the American Cancer Society. Prior to accepting the Inova appointment Dr. Trump led the renewal of RPCI’s $19 million, 5-year designation as a comprehensive cancer center by the National Cancer Institute. His personal research work involved the development of vitamin D-based approaches to cancer prevention and therapy. Dr. Trump has had previous appointments with the University of Pittsburgh Cancer Institute and School of Medicine, Duke University Medical Center, University of Wisconsin, and the Johns Hopkins University. Since his assuming the position of CEO, ISCI in 2015, he has recruited more the 30 cancer clinicians and scientists to develop ISCI program in drug discovery, biomarker development, clinical genomics and clinical cancer trials. ISCI established the first Molecular Tumor Board in the Spring of 2016.
Dr. Trump earned his medical degree at Johns Hopkins University School of Medicine in Baltimore, where he also completed his internship and resident training. He served as chief resident in internal medicine at Johns Hopkins Hospital.